245 related articles for article (PubMed ID: 34251707)
1. Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response.
Na JE; Sinn DH; Lee JH; Jang HJ; Baek SY; Kim KA; Kang WS; Gwak GY; Paik YH; Kim YJ; Choi MS; Yoon JH; Lee JH; Koh KC; Paik SW
J Viral Hepat; 2021 Oct; 28(10):1392-1399. PubMed ID: 34251707
[TBL] [Abstract][Full Text] [Related]
2. Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.
Choi J; Kim HJ; Lee J; Cho S; Ko MJ; Lim YS
JAMA Oncol; 2019 Jan; 5(1):30-36. PubMed ID: 30267080
[TBL] [Abstract][Full Text] [Related]
3. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China.
Yip TC; Wong VW; Chan HL; Tse YK; Lui GC; Wong GL
Gastroenterology; 2020 Jan; 158(1):215-225.e6. PubMed ID: 31574268
[TBL] [Abstract][Full Text] [Related]
5. The Different Prognoses of Hepatocellular Carcinoma with Previous Tenofovir versus Entecavir Treatment for Chronic Hepatitis B Virus: Analysis Based on 15 Propensity Score-Matched Studies.
Hou J; Qiang Z; Li Y; Zhang Y
Dig Dis; 2023; 41(3):476-488. PubMed ID: 36535244
[TBL] [Abstract][Full Text] [Related]
6. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
[TBL] [Abstract][Full Text] [Related]
7. No Difference in Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection Treated With Entecavir vs Tenofovir.
Oh H; Yoon EL; Jun DW; Ahn SB; Lee HY; Jeong JY; Kim HS; Jeong SW; Kim SE; Shim JJ; Sohn JH; Cho YK;
Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2793-2802.e6. PubMed ID: 32135246
[TBL] [Abstract][Full Text] [Related]
8. Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B.
Lee HW; Cho YY; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK; Park SY
Hepatol Int; 2021 Oct; 15(5):1083-1092. PubMed ID: 34402025
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Efficacy of Entecavir and Tenofovir in Reducing Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients: A Real-Life Study in Turkey.
Güzelbulut F; Gökçen P; Can G; Adalı G; Değirmenci Saltürk AG; Aslan E; Özdil K; Doğanay HL
Turk J Gastroenterol; 2021 Apr; 32(4):412-421. PubMed ID: 34231488
[TBL] [Abstract][Full Text] [Related]
10. Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis.
Choi WM; Choi J; Lim YS
Clin Gastroenterol Hepatol; 2021 Feb; 19(2):246-258.e9. PubMed ID: 32407970
[TBL] [Abstract][Full Text] [Related]
11. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis.
Ha I; Chung JW; Jang ES; Jeong SH; Kim JW
J Gastroenterol Hepatol; 2020 Oct; 35(10):1774-1781. PubMed ID: 32154938
[TBL] [Abstract][Full Text] [Related]
13. Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma.
Lee SW; Choi J; Kim SU; Lim YS
Clin Mol Hepatol; 2021 Jul; 27(3):402-412. PubMed ID: 34157830
[TBL] [Abstract][Full Text] [Related]
14. No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis.
Yuan J; Peng Y; Hao FB; Wang YQ; Wang CR; Zhong GC
Aging (Albany NY); 2021 Feb; 13(5):7147-7165. PubMed ID: 33658397
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
[TBL] [Abstract][Full Text] [Related]
16. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.
Lee SW; Kwon JH; Lee HL; Yoo SH; Nam HC; Sung PS; Nam SW; Bae SH; Choi JY; Yoon SK; Han NI; Jang JW
Gut; 2020 Jul; 69(7):1301-1308. PubMed ID: 31672838
[TBL] [Abstract][Full Text] [Related]
17. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.
Tseng CH; Tseng CM; Wu JL; Hsu YC; El-Serag HB
J Gastroenterol Hepatol; 2020 Oct; 35(10):1684-1693. PubMed ID: 32343431
[TBL] [Abstract][Full Text] [Related]
18. Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea.
Choi H; Seo GH
J Korean Med Sci; 2021 Apr; 36(14):e89. PubMed ID: 33847080
[TBL] [Abstract][Full Text] [Related]
19. Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis.
Goyal SK; Dixit VK; Shukla SK; Ghosh J; Behera M; Tripathi M; Gupta N; Ranjan A; Jain AK
Indian J Gastroenterol; 2015 Jul; 34(4):286-91. PubMed ID: 26243587
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis.
Zhang Z; Zhou Y; Yang J; Hu K; Huang Y
BMC Cancer; 2019 May; 19(1):511. PubMed ID: 31142283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
